Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 1.00 |
| ▸ | RET | P07949 | 5/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | KIF5B | P33176 | 1/20 | 1.00 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 1.00 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.97 |
| ▸ | RAF1 | P04049 | 4/20 | 0.77 |
| ▸ | BRAF | P15056 | 3/20 | 0.77 |
| ▸ | EGFR | P00533 | 11/20 | 0.77 |
| ▸ | SRC | P12931 | 3/20 | 0.75 |
| ▸ | GAK | O14976 | 2/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | STK10 | O94804 | 1/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249695 | 1.00 | KDR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL29435034 | 1.00 | KDR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| Hydrochloric Acid SCHEMBL30433676 | 0.99 | NOD1 (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL5565577 | 0.88 | FGFR1 (0.78) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL15052582 | 0.87 | BRAF (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL31060707 | 0.86 | EGFR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL5482883 | 0.86 | EGFR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL5474772 | 0.86 | KDR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL5569018 | 0.86 | KDR (1.00) | KDRRETFGFR1FLT1EPHB2 | |
| SCHEMBL15051582 | 0.85 | BRAF (1.00) | KDRRETFGFR1FLT1EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| CN-107904201-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2021-11-16 | — | — | CN | claimed |
| CN-107904201-A | Differentiation of the human embryo stem cell to pancreatic endocrine pedigree | 詹森生物科技公司 | 2018-04-13 | — | — | CN | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20060276491-A9 | Therapeutic compounds | PARKER HUGHES INSTITUTE (US) | 2006-12-07 | — | — | US | claimed |
| EP-1105378-B1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INST (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040192711-A1 | Therapeutic compounds | PARKER HUGHES INSTITUTE | 2004-09-30 | — | — | US | claimed |
| US-20040034045-A1 | Inhibitors of thrombin induced platelet aggregation | PARKER HUGHES INSTITUTE (US) | 2004-02-19 | — | — | US | claimed |
| US-20020055514-A1 | JAK-3 inhibitors for treating allergic disorders | PARKER HUGHES INSTITUTE (US) | 2002-05-09 | — | — | US | claimed |
| US-20020042513-A1 | Therapeutic compounds | PARKER HUGHES INSTITUTE | 2002-04-11 | — | — | US | claimed |
| EP-1158968-A2 | JAK-3 INHIBITORS FOR TREATING ALLERGIC DISORDERS | Parker Hughes Institute (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | PARKER HUGHES INSTITUTE (US) | 2001-11-22 | — | — | US | claimed |
| US-6313130-B1 | PATHOLOGY WHEREIN MAST CELL ACTIVATION OR DEGRANULATION IS IMPLICATED AND INHIBITION OF MAST CELL ACTIVATION OR DEGRANULATION IS DESIRED BY ADMINISTERING A JAUS KINASE-3 INHIBITOR TO MAMMAL | PARKER HUGHES INSTITUTE | 2001-11-06 | — | — | US | claimed |
| US-6313129-B1 | ADMINISTERING TO A MAMMAL QUINAZOLINE DERIVATIVE FOR THERAPY OF ORGAN TRANSPLANT REJECTION | HUGHES INSTITUTE | 2001-11-06 | — | — | US | claimed |
| WO-2001045641-A2 | INHIBITORS OF THROMBIN INDUCED PLATELET AGGREGATION | PARKER HUGHES INSTITUTE (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1105378-A1 | QUINAZOLINE DERIVATIVES | Parker Hughes Institute (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000051587-A2 | JAK-3 INHIBITORS FOR TREATING ALLERGIC DISORDERS | PARKER HUGHES INSTITUTE (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000010981-A1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INSTITUTE (US) | 2000-03-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034045-A1 | Inhibitors of thrombin induced platelet aggregation | JAK2, JAK3, JAK1 | KDR 1041/4885RET 284/4885FGFR1 471/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | KDR 2926/4885RET 1253/4885FGFR1 135/4885 |
| US-20060276491-A9 | Therapeutic compounds | JAK3, JAK1, JAK2 | KDR 1653/4885RET 1658/4885FGFR1 484/4885 |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | JAK3, JAK1, JAK2 | KDR 1247/4885RET 1580/4885FGFR1 661/4885 |
| US-20020055514-A1 | JAK-3 inhibitors for treating allergic disorders | JAK3, JAK1, JAK2 | KDR 1636/4885RET 1504/4885FGFR1 3828/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | KDR 2926/4885RET 1253/4885FGFR1 135/4885 |
| US-20040192711-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | KDR 1653/4885RET 1658/4885FGFR1 484/4885 |
| US-20020042513-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | KDR 1653/4885RET 1658/4885FGFR1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.